| ALLIANCE-PHARMA-SOLUTIONS |
ALLIANCE-PHARMA-SOLUTIONS |
85%
|
the Company entered into Membership Interest Purchase Agreements to sell 100% of the outstanding membership interests of the Company's former subsidiaries, Alliance Pharma Solutions, LLC |
| ALLIANCE-PHARMA-SOLUTIONS-LLC |
ALLIANCE-PHARMA-SOLUTIONS-LLC |
85%
|
On January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100% of the outstanding membership interests of the Company's former subsidiaries, Alliance Pharma Soluti… |
| COMMUNITY-SPECIALTY-PHARMACY |
COMMUNITY-SPECIALTY-PHARMACY |
85%
|
the Company entered into Membership Interest Purchase Agreements to sell 100% of the outstanding membership interests of the Company's former subsidiaries, Community Specialty Pharmacy, LLC |
| COMMUNITY-SPECIALTY-PHARMACY-LLC |
COMMUNITY-SPECIALTY-PHARMACY-LLC |
85%
|
On January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100% of the outstanding membership interests of the Company's former subsidiaries, Community Specialty Ph… |
| SUPERLATUS-FOODS-INC |
SUPERLATUS-FOODS-INC |
85%
|
the Company entered in a Stock Purchase Agreement with Superlatus Foods Inc |
| SUPERLATUS-INC |
SUPERLATUS-INC |
85%
|
the Company entered into an Amended and Restated Agreement and Plan of Merger with Superlatus Inc |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from SCNX graph: supplements to approved applications; ● require revisions to the labeling, including limitations on approved uses or… |
| ORANY |
ORANY |
72%
|
supplements to approved applications; ● require revisions to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other safety information… |
| WGRX |
Wellgistics Health, Inc. |
72%
|
Reciprocal relationship from WGRX graph: Reciprocal relationship from SCNX graph: erience, and other currently available evidence. Other Receivables As of December 31, 2024 and 2023, other receivable… |
| WGRX |
Wellgistics Health, Inc. |
72%
|
erience, and other currently available evidence. Other Receivables As of December 31, 2024 and 2023, other receivables are $ and $ . As of December 31, 2024, other receivables primarily consist of sh… |
| BLUEBIRD-EXPLORATION-COMPANY |
BLUEBIRD-EXPLORATION-COMPANY |
62%
|
ed to sell all issued and outstanding shares of common stock of Bonum Health, Inc. In November 2025, the Company dissolved Bonum Health, LLC. The divestitures described above are part of a broader st… |
| BONUM-HEALTH-INC |
BONUM-HEALTH-INC |
62%
|
ed to sell all issued and outstanding shares of common stock of Bonum Health, Inc. In November 2025, the Company dissolved Bonum Health, LLC. The divestitures described above are part of a broader st… |
| BONUM-HEALTH-LLC |
BONUM-HEALTH-LLC |
62%
|
ed to sell all issued and outstanding shares of common stock of Bonum Health, Inc. In November 2025, the Company dissolved Bonum Health, LLC. The divestitures described above are part of a broader st… |
| BONUM-HEALTH-LLC-BONUM-HEALTH-INC |
BONUM-HEALTH-LLC-BONUM-HEALTH-INC |
62%
|
address unmet medical needs. Its targeted portfolio consists of short term and long-term opportunities with efficient development, regulatory, and go to market strategies. After our acquisition of Sc… |
| CALCIUM-CHANNEL-BLOCKERS-SCIENTURE-LLC |
CALCIUM-CHANNEL-BLOCKERS-SCIENTURE-LLC |
62%
|
. This sales and marketing organization will include a combination of field teams, virtual sales representatives and omnichannel marketing to effectively reach health care providers and offer patient… |
| COMPETITION-SCIENTURE-LLC |
COMPETITION-SCIENTURE-LLC |
62%
|
. This sales and marketing organization will include a combination of field teams, virtual sales representatives and omnichannel marketing to effectively reach health care providers and offer patient… |
| IF-SCIENTURE-LLC |
IF-SCIENTURE-LLC |
62%
|
idly evolving fields, and Scienture LLC has not yet demonstrated an ability to successfully overcome such risks and difficulties. If Scienture LLC does not address these risks and difficulties succes… |
| INTEGRAL-HEALTH-INC |
INTEGRAL-HEALTH-INC |
62%
|
. On June 24, 2025, the promissory note was assigned by Tollo to Integral Health, Inc. In August 2025, Integral Health, including its subsidiary IPS, were acquired by third parties. Therefore, as of … |
| INTEGRA-PHARMA-SOLUTIONS-LLC |
INTEGRA-PHARMA-SOLUTIONS-LLC |
62%
|
address unmet medical needs. Its targeted portfolio consists of short term and long-term opportunities with efficient development, regulatory, and go to market strategies. After our acquisition of Sc… |
| MICRO-MERCHANT-SYSTEMS-INC |
MICRO-MERCHANT-SYSTEMS-INC |
62%
|
2024 Revenue $ 636,643 Net loss from continuing operations $ ( 19,459,955 ) Net loss from continuing operations per share $ ( 5.77 ) 83 Table of Contents Dispositions and Divestitures Refer to Note 1… |
| MMSI |
Merit Medical Systems, Inc. |
62%
|
Reciprocal relationship from MMSI graph: Reciprocal relationship from SCNX graph: Reciprocal relationship from MMSI graph: Reciprocal relationship from SCNX graph: 2024 Revenue $ 636,643 Net loss fro… |
| NALOXONE-HCL-NASAL-SPRAY-SCIENTURE-LLC |
NALOXONE-HCL-NASAL-SPRAY-SCIENTURE-LLC |
62%
|
wth and profitability. Using dedicated sales and marketing resources in the U.S., which Scienture is in the process of building, Scienture will seek to begin to generate revenues and then drive the r… |
| NEBRASKA-LIMITED-LIABILITY-COMPANY |
NEBRASKA-LIMITED-LIABILITY-COMPANY |
62%
|
The following is a summary of the First Closing Debentures: SCHEDULE OF THE ARENA DEBENTURES Arena Note Convertible debenture - Arena Principal $ 3,333,333 Original issuance discount ( 333,333 ) Othe… |
| NVK-FINANCE-LLC |
NVK-FINANCE-LLC |
62%
|
The following is a summary of the First Closing Debentures: SCHEDULE OF THE ARENA DEBENTURES Arena Note Convertible debenture - Arena Principal $ 3,333,333 Original issuance discount ( 333,333 ) Othe… |
| SUMMIT-BIOSCIENCES-INC |
SUMMIT-BIOSCIENCES-INC |
62%
|
wth and profitability. Using dedicated sales and marketing resources in the U.S., which Scienture is in the process of building, Scienture will seek to begin to generate revenues and then drive the r… |
| TRXADE-GROUP-INC |
TRXADE-GROUP-INC |
62%
|
ed to sell all issued and outstanding shares of common stock of Bonum Health, Inc. In November 2025, the Company dissolved Bonum Health, LLC. The divestitures described above are part of a broader st… |
| TRXADE-HEALTH-INC |
TRXADE-HEALTH-INC |
62%
|
address unmet medical needs. Its targeted portfolio consists of short term and long-term opportunities with efficient development, regulatory, and go to market strategies. After our acquisition of Sc… |
| U-S-SCIENTURE-LLC |
U-S-SCIENTURE-LLC |
62%
|
ical companies to commercialize its products outside of the U.S. Scienture LLC is in the process of building a commercial sales and marketing operation in the U.S., through a partnership with a Contr… |
| WOOD-SAGE-LLC |
WOOD-SAGE-LLC |
62%
|
. The loan was unsecured, interest bearing at the minimum applicable federal rate per annum, and due on demand. The loans were fully repaid in October 2025. Consequently, there were no amounts outsta… |
| XCELLINK-INTERNATIONAL-INC |
XCELLINK-INTERNATIONAL-INC |
62%
|
ed to sell all issued and outstanding shares of common stock of Bonum Health, Inc. In November 2025, the Company dissolved Bonum Health, LLC. The divestitures described above are part of a broader st… |
